查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1836370

2032 年脂質體阿黴素市場預測：按產品類型、分銷管道、應用、最終用戶和地區進行的全球分析

Liposomal Doxorubicin Market Forecasts to 2032 - Global Analysis By Product Type (Doxil / Caelyx, Myocet, Lipodox, and Other Liposomal Formulations), Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球脂質體阿黴素市場預計在 2025 年達到 14.2 億美元，預計到 2032 年將達到 26.1 億美元，預測期內的複合年成長率為 9.0%。

脂質體阿黴素是阿黴素的升級版，其設計將藥物包裹在脂質體中，以提高療效和安全性。這種劑型延長了藥物在血液中的停留時間，並最大限度地減少了不良副作用，尤其是心臟毒性。脂質體在卵巢癌、乳癌、多發性骨髓瘤和卡波西氏肉瘤的治療中扮演重要角色。脂質體阿黴素提供標靶藥物輸送，與傳統阿黴素相比，其療效更高。

根據劍橋大學估計，到2040年，全球乳癌患者數預計將達到300多萬人。

對標靶有效化療的需求不斷增加

對精準醫療的日益重視推動了對脂質體阿黴素作為標靶化療的需求。脂質體能夠將細胞毒藥物直接輸送到癌細胞，同時最大限度地減少全身暴露，這正在徹底改變癌症治療通訊協定。奈米技術和脂質體藥物傳輸系統的進步正在提高治療效果並減少副作用。隨著全球癌症發生率的上升，醫療保健提供者擴大採用脂質體製劑來改善患者的治療效果。人工智慧在癌症診斷中的整合也支援個人化化療方案。總之，這些因素促成了脂質體阿黴素在現代癌症治療中的廣泛應用。

製造流程複雜且高成本

生產脂質體阿黴素需要複雜的配方技術和嚴格的品管措施，導致成本高且技術負擔沉重。保持粒徑均勻性和包封率需要專門的設備和熟練的人員。遵守GMP和FDA指南等標準會增加額外的複雜性和成本。人們正在探索連續生產和自動化等新技術以簡化生產流程，但其應用仍然有限。小型製造商在擴大業務方面面臨挑戰，因為高昂的資本投入和先進設備的有限取得。這些障礙可能會減緩市場擴張並限制產品供應。

聯合治療開發

人們對聯合治療日益成長的興趣為脂質體阿黴素與免疫療法、標靶藥物和放射線治療的聯合應用提供了重要機會。這種多重藥物聯合治療有望提高治療效果並克服抗藥性。生物標記主導的治療選擇方面的創新使得能夠根據個別患者情況制定更精確的聯合方案。臨床試驗擴大探索脂質體阿黴素與查核點和激酶抑制劑的協同作用。伴隨診斷的興起促進了患者分層和治療最佳化。隨著腫瘤學向綜合治療模式發展，脂質體阿黴素將在組合方案中發揮核心作用。

可能的副作用和毒性

儘管脂質體阿黴素具有標靶遞送功能，但仍可能引起心臟毒性、手足症候群和骨髓抑制等副作用。這些風險可能會限制其在某些患者群體中的使用，尤其是那些已有潛在疾病的患者。正在進行的研究致力於改進脂質體製劑，以提高其安全性並減少脫靶效應。聚合物奈米顆粒和抗體藥物複合體等替代藥物遞送平台的出現構成了競爭威脅。關於長期毒性和上市後監測的監管審查也日益嚴格。如果不在製劑和病患監測方面持續創新，安全問題可能會減緩市場成長。

COVID-19的影響：

新冠疫情擾亂了癌症治療途徑，延誤了許多癌症患者的診斷和治療時間。供應鏈中斷影響了脂質體阿黴素和其他化療藥物的供應。然而，這場危機加速了遠端醫療和遠端患者監護的普及，重塑了癌症治療的模式。監管機構已實施緊急通訊協定，以確保治療的連續性，包括加速關鍵藥物的核准。疫情後的復甦正促使市場對韌性製造和去中心化分銷模式進行再投資。這些轉變預計將增強脂質體阿黴素市場的適應性和長期成長前景。

預計乳癌將成為預測期內最大的癌症類別

由於乳癌在全球的高發病率和完善的治療方案，預計該領域將在預測期內佔據最大的市場佔有率。脂質體阿黴素廣泛用於治療轉移性和復發性乳癌，與傳統製劑相比，其耐受性更高。影像學和分子分析技術的進步使得更早發現和更有針對性的治療成為可能。目前，臨床指引建議有心臟風險因子的患者使用脂質體製劑，進一步加速了其應用。正在進行的臨床試驗正在評估荷爾蒙療法和HER2標靶治療聯合治療的療效。這些進展鞏固了乳癌治療在市場上的主導地位。

預計居家照護領域在預測期內將實現最高複合年成長率

預計在預測期內，居家醫療領域將呈現最高成長率，這得益於癌症治療向門診和自行給藥的轉變。脂質體阿黴素良好的安全性和較低的住院需求使其非常適合家庭治療模式。穿戴式輸液設備和遠端監控技術的創新正在提高患者的便利性和依從性。醫療保健系統正在推廣分散式醫療，以降低成本並改善醫療可近性，尤其是在農村和服務不足地區。報銷框架正在不斷發展，以支持家庭化療的發展。

佔比最高的地區

預計亞太地區將在預測期內佔據最大的市場佔有率，這得益於癌症發病率的上升和醫療基礎設施的不斷擴張。中國、印度和日本等國家正大力投資腫瘤學研究和國內製藥生產。政府正透過補貼和加速核准舉措鼓勵採用先進的治療方法。該地區的臨床試驗以及全球和本地製藥公司之間的合作正在活性化。人工智慧診斷和遠距腫瘤學平台等技術的採用正在加速治療的可及性。

複合年成長率最高的地區：

在預測期內，北美預計將見證最高的複合年成長率，這得益於強勁的研發投入和創新癌症療法的早期應用。美國和加拿大在開發下一代脂質體製劑和組合方案處於領先地位。監管機構正在簡化突破性抗癌藥物的核准途徑，提高市場彈性。醫院和癌症中心擴大採用數位化工具來制定個人化治療方案和追蹤患者。優惠的報銷政策和較高的認知度正在推動對先進化療方案的需求。隨著精準腫瘤學的發展勢頭強勁，北美將繼續成為全球市場成長的標竿。

免費客製化服務：

此報告的訂閱者可以使用以下免費自訂選項之一：

  • 公司簡介
    • 對最多三家其他市場公司進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球脂質體阿黴素市場（依產品類型）

  • Doxil/凱利克斯
  • Mio 套裝
  • 脂質體
  • 其他脂質體製劑

6. 全球脂質體阿黴素市場依分銷管道分類

  • 醫院藥房
  • 網路藥局
  • 零售藥局

7. 全球脂質體阿黴素市場（依應用）

  • 乳癌
  • 卵巢癌
  • 子宮內膜癌
  • 卡波西氏肉瘤
  • 多發性骨髓瘤
  • 白血病
  • 腎癌
  • 骨癌
  • 其他

8. 全球脂質體阿黴素市場（以最終用戶分類）

  • 醫院
  • 專科診所
  • 居家照護
  • 其他

9. 全球脂質體阿黴素市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第10章：重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司概況

  • Johnson & Johnson
  • Sandoz
  • Sun Pharmaceutical Industries Ltd.
  • Zydus Cadila
  • Pfizer Inc.
  • Intas Pharmaceuticals Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Formosa Laboratories, Inc.
  • Celsion Corporation
  • Pacira BioSciences, Inc.
  • Gilead Sciences, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eagle Pharmaceuticals, Inc.
  • Ligand Pharmaceuticals
Product Code: SMRC31494

According to Stratistics MRC, the Global Liposomal Doxorubicin Market is accounted for $1.42 billion in 2025 and is expected to reach $2.61 billion by 2032 growing at a CAGR of 9.0% during the forecast period. Liposomal doxorubicin is an advanced version of doxorubicin, designed by enclosing the drug in liposomes for improved efficacy and safety. This formulation prolongs the drug's presence in the bloodstream and minimizes harmful side effects, especially cardiotoxicity. Commonly prescribed in oncology, it plays an important role in treating conditions such as ovarian cancer, breast cancer, multiple myeloma, and Kaposi's sarcoma. By offering targeted drug delivery, liposomal doxorubicin provides enhanced therapeutic benefits compared to conventional doxorubicin.

According to Cambridge University estimates, the global number of breast cancer cases is expected to reach over 3 million by 2040.

Market Dynamics:

Driver:

Rising demand for targeted & effective chemotherapy

The growing emphasis on precision medicine is fueling demand for liposomal doxorubicin as a targeted chemotherapy option. Its ability to deliver cytotoxic agents directly to tumor cells while minimizing systemic exposure is revolutionizing cancer treatment protocols. Advancements in nanotechnology and lipid-based drug delivery systems are enhancing therapeutic efficacy and reducing adverse effects. As cancer prevalence rises globally, healthcare providers are increasingly adopting liposomal formulations for improved patient outcomes. The integration of AI in oncology diagnostics is also supporting personalized chemotherapy regimens. These factors collectively contribute to the expanding footprint of liposomal doxorubicin in modern cancer care.

Restraint:

Complex and high-cost manufacturing process

The production of liposomal doxorubicin involves intricate formulation techniques and stringent quality control measures, making it both costly and technically demanding. Specialized equipment and skilled personnel are required to maintain particle size uniformity and encapsulation efficiency. Regulatory compliance with standards like GMP and FDA guidelines adds further complexity and expense. Emerging technologies such as continuous manufacturing and automation are being explored to streamline production, but adoption remains limited. Smaller manufacturers face challenges in scaling operations due to high capital investment and limited access to advanced facilities. These hurdles can slow market expansion and restrict product availability.

Opportunity:

Development of combination therapies

The growing interest in combination therapies presents a significant opportunity for liposomal doxorubicin to be paired with immunotherapies, targeted agents, or radiation. Such multi-modal approaches are showing promise in enhancing treatment efficacy and overcoming drug resistance. Innovations in biomarker-driven therapy selection are enabling more precise combinations tailored to individual patient profiles. Clinical trials are increasingly exploring synergistic effects between liposomal doxorubicin and checkpoint inhibitors or kinase inhibitors. The rise of companion diagnostics is facilitating better patient stratification and therapy optimization. As oncology moves toward integrated treatment models, liposomal doxorubicin is poised to play a central role in combination regimens.

Threat:

Potential side effects and toxicity

Despite its targeted delivery, liposomal doxorubicin can still cause adverse effects such as cardiotoxicity, hand-foot syndrome, and myelosuppression. These risks may limit its use in certain patient populations, especially those with pre-existing conditions. Ongoing research is focused on refining liposomal formulations to improve safety profiles and reduce off-target effects. The emergence of alternative drug delivery platforms, such as polymeric nanoparticles and antibody-drug conjugates, poses competitive threats. Regulatory scrutiny around long-term toxicity and post-marketing surveillance is intensifying. Without continued innovation in formulation and patient monitoring, safety concerns could dampen market growth.

Covid-19 Impact:

The COVID-19 pandemic disrupted oncology care pathways, delaying diagnoses and treatment schedules for many cancer patients. Supply chain interruptions affected the availability of liposomal doxorubicin and other chemotherapy agents. However, the crisis accelerated the adoption of telemedicine and remote patient monitoring, reshaping cancer care delivery. Regulatory bodies introduced emergency protocols to ensure continuity of treatment, including fast-tracked approvals for critical drugs. Post-pandemic recovery is driving renewed investment in resilient manufacturing and decentralized distribution models. These shifts are expected to strengthen the liposomal doxorubicin market's adaptability and long-term growth prospects.

The breast cancer segment is expected to be the largest during the forecast period

The breast cancer segment is expected to account for the largest market share during the forecast period, due to its high global incidence and established treatment protocols. Liposomal doxorubicin is widely used in metastatic and recurrent breast cancer cases, offering improved tolerability over conventional formulations. Technological advancements in imaging and molecular profiling are enabling earlier detection and more targeted therapy. Clinical guidelines increasingly recommend liposomal formulations for patients with cardiac risk factors, further boosting adoption. Ongoing trials are evaluating its efficacy in combination with hormonal and HER2-targeted therapies. These developments reinforce breast cancer's leading position in the market.

The homecare segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the homecare segment is predicted to witness the highest growth rate, driven by the shift toward outpatient and self-administered cancer therapies. Liposomal doxorubicin's favorable safety profile and reduced hospitalization needs make it suitable for home-based treatment models. Innovations in wearable infusion devices and remote monitoring technologies are enhancing patient convenience and adherence. Healthcare systems are promoting decentralized care to reduce costs and improve access, especially in rural and underserved areas. Reimbursement frameworks are evolving to support home-based chemotherapy delivery.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, supported by rising cancer prevalence and expanding healthcare infrastructure. Countries like China, India, and Japan are investing heavily in oncology research and domestic drug manufacturing. Government initiatives are encouraging the adoption of advanced therapies through subsidies and fast-track approvals. The region is witnessing increased clinical trial activity and partnerships between global pharma firms and local players. Technological adoption, including AI-driven diagnostics and tele-oncology platforms, is accelerating treatment access.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, fueled by robust R&D investment and early adoption of innovative cancer therapies. The U.S. and Canada are at the forefront of developing next-generation liposomal formulations and combination regimens. Regulatory agencies are streamlining approval pathways for breakthrough oncology drugs, enhancing market agility. Hospitals and cancer centers are integrating digital tools for personalized treatment planning and patient tracking. Favorable reimbursement policies and high awareness levels are driving demand for advanced chemotherapy options. As precision oncology gains momentum, North America continues to set the benchmark for global market growth.

Key players in the market

Some of the key players in Liposomal Doxorubicin Market include Johnson & Johnson, Sandoz, Sun Pharmaceutical Industries Ltd., Zydus Cadila, Pfizer Inc., Intas Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Formosa Laboratories, Inc., Celsion Corporation, Pacira BioSciences, Inc., Gilead Sciences, Inc., Dr. Reddy's Laboratories Ltd., Eisai Co., Ltd., Eagle Pharmaceuticals, Inc., and Ligand Pharmaceuticals.

Key Developments:

In September 2025, The Johnson & Johnson (J&J) announced a $5 million investment in the Africa Frontline First (AFF) Catalytic Fund, a fund hosted by the Global Fund to Fight AIDS, TB & Malaria. As an AFF Catalytic Fund founding supporter, the J&J Foundation's total pledge has now increased to a total of $20 million for the training and deployment of 200,000 professional community health workers (CHWs) into national health systems across Africa.

In May 2025, Sun Pharmaceutical Industries Limited announced the completion of its acquisition of Checkpoint Therapeutics, Inc., an immunotherapy and targeted Oncology Company. As part of the acquisition, Sun Pharma acquires UNLOXCYTTM, the first and only FDAapproved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma.

Product Types Covered:

  • Doxil / Caelyx
  • Myocet
  • Lipodox
  • Other Liposomal Formulations
  • Other Product Types

Distribution Channels Covered:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

Applications Covered:

  • Breast Cancer
  • Ovarian Cancer
  • Endometrial Cancer
  • Kaposi Sarcoma
  • Multiple Myeloma
  • Leukemia
  • Kidney Cancer
  • Bone Sarcoma
  • Other Applications

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Liposomal Doxorubicin Market, By Product Type

  • 5.1 Introduction
  • 5.2 Doxil / Caelyx
  • 5.3 Myocet
  • 5.4 Lipodox
  • 5.5 Other Liposomal Formulations

6 Global Liposomal Doxorubicin Market, By Distribution Channel

  • 6.1 Introduction
  • 6.2 Hospital Pharmacies
  • 6.3 Online Pharmacies
  • 6.4 Retail Pharmacies

7 Global Liposomal Doxorubicin Market, By Application

  • 7.1 Introduction
  • 7.2 Breast Cancer
  • 7.3 Ovarian Cancer
  • 7.4 Endometrial Cancer
  • 7.5 Kaposi Sarcoma
  • 7.6 Multiple Myeloma
  • 7.7 Leukemia
  • 7.8 Kidney Cancer
  • 7.9 Bone Sarcoma
  • 7.10 Other Applications

8 Global Liposomal Doxorubicin Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals
  • 8.3 Specialty Clinics
  • 8.4 Homecare
  • 8.5 Other End Users

9 Global Liposomal Doxorubicin Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Johnson & Johnson
  • 11.2 Sandoz
  • 11.3 Sun Pharmaceutical Industries Ltd.
  • 11.4 Zydus Cadila
  • 11.5 Pfizer Inc.
  • 11.6 Intas Pharmaceuticals Ltd.
  • 11.7 Teva Pharmaceutical Industries Ltd.
  • 11.8 Formosa Laboratories, Inc.
  • 11.9 Celsion Corporation
  • 11.10 Pacira BioSciences, Inc.
  • 11.11 Gilead Sciences, Inc.
  • 11.12 Dr. Reddy's Laboratories Ltd.
  • 11.13 Eisai Co., Ltd.
  • 11.14 Eagle Pharmaceuticals, Inc.
  • 11.15 Ligand Pharmaceuticals

List of Tables

  • Table 1 Global Liposomal Doxorubicin Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Liposomal Doxorubicin Market Outlook, By Product Type (2024-2032) ($MN)
  • Table 3 Global Liposomal Doxorubicin Market Outlook, By Doxil / Caelyx (2024-2032) ($MN)
  • Table 4 Global Liposomal Doxorubicin Market Outlook, By Myocet (2024-2032) ($MN)
  • Table 5 Global Liposomal Doxorubicin Market Outlook, By Lipodox (2024-2032) ($MN)
  • Table 6 Global Liposomal Doxorubicin Market Outlook, By Other Liposomal Formulations (2024-2032) ($MN)
  • Table 7 Global Liposomal Doxorubicin Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 8 Global Liposomal Doxorubicin Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 9 Global Liposomal Doxorubicin Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 10 Global Liposomal Doxorubicin Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 11 Global Liposomal Doxorubicin Market Outlook, By Application (2024-2032) ($MN)
  • Table 12 Global Liposomal Doxorubicin Market Outlook, By Breast Cancer (2024-2032) ($MN)
  • Table 13 Global Liposomal Doxorubicin Market Outlook, By Ovarian Cancer (2024-2032) ($MN)
  • Table 14 Global Liposomal Doxorubicin Market Outlook, By Endometrial Cancer (2024-2032) ($MN)
  • Table 15 Global Liposomal Doxorubicin Market Outlook, By Kaposi Sarcoma (2024-2032) ($MN)
  • Table 16 Global Liposomal Doxorubicin Market Outlook, By Multiple Myeloma (2024-2032) ($MN)
  • Table 17 Global Liposomal Doxorubicin Market Outlook, By Leukemia (2024-2032) ($MN)
  • Table 18 Global Liposomal Doxorubicin Market Outlook, By Kidney Cancer (2024-2032) ($MN)
  • Table 19 Global Liposomal Doxorubicin Market Outlook, By Bone Sarcoma (2024-2032) ($MN)
  • Table 20 Global Liposomal Doxorubicin Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 21 Global Liposomal Doxorubicin Market Outlook, By End User (2024-2032) ($MN)
  • Table 22 Global Liposomal Doxorubicin Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 23 Global Liposomal Doxorubicin Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 24 Global Liposomal Doxorubicin Market Outlook, By Homecare (2024-2032) ($MN)
  • Table 25 Global Liposomal Doxorubicin Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.